Keyword: Dendreon

Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.

Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.

The sale gives Dendreon better access to capital for expansion and deals, its top executive said—perhaps into CAR-T or other cell therapies, an area where the company is already eyeing deals.

Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.

Dendreon’s chairwoman said the infrastructure developed to produce and market Provenge has paved its way into CAR-T.

Valeant's third-quarter results provided a welcome dose of good news as the company works to execute its lengthy turnaround.

After paying $1 billion for Sprout and its controversial female libido pill Addyi, Valeant is giving up.

Valeant is in talks to sell its Bausch & Lomb eye surgery business to Carl Zeiss Meditec for potentially $2 billion, Bloomberg reports.

Dendreon unveiled new data at ASCO showing Provenge generates a killer T-cell response that correlates with overall survival.

Years after winning Provenge's FDA approval—and struggling to make it a commercial success—Dendreon has racked up some data it hopes can help.